• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Role of Cytochrome P450 2C8 in Drug-Drug Interaction between Amiodarone and Nirmatrelvir/Ritonavir Via Physiologically-Based Pharmacokinetic Modeling.

作者信息

Wang Ziteng, Chan Eric Chun Yong

机构信息

Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, Singapore.

出版信息

Clin Pharmacol Ther. 2023 Jun;113(6):1183-1184. doi: 10.1002/cpt.2885. Epub 2023 Mar 16.

DOI:10.1002/cpt.2885
PMID:36924458
Abstract
摘要

相似文献

1
Role of Cytochrome P450 2C8 in Drug-Drug Interaction between Amiodarone and Nirmatrelvir/Ritonavir Via Physiologically-Based Pharmacokinetic Modeling.通过基于生理的药代动力学模型研究细胞色素P450 2C8在胺碘酮与奈玛特韦/利托那韦药物相互作用中的作用
Clin Pharmacol Ther. 2023 Jun;113(6):1183-1184. doi: 10.1002/cpt.2885. Epub 2023 Mar 16.
2
Physiologically-Based Pharmacokinetic-Led Guidance for Patients With Cystic Fibrosis Taking Elexacaftor-Tezacaftor-Ivacaftor With Nirmatrelvir-Ritonavir for the Treatment of COVID-19.基于生理的药代动力学引导用于 COVID-19 治疗中接受 Elexacaftor-Tezacaftor-Ivacaftor 联合奈玛特韦-利托那韦治疗的囊性纤维化患者。
Clin Pharmacol Ther. 2022 Jun;111(6):1324-1333. doi: 10.1002/cpt.2585. Epub 2022 Apr 6.
3
Physiologically-Based Pharmacokinetic Modeling-Guided Dose Management of Oral Anticoagulants when Initiating Nirmatrelvir/Ritonavir (Paxlovid) for COVID-19 Treatment.基于生理的药代动力学模型指导下口服抗凝药物在 COVID-19 治疗中起始使用奈玛特韦/利托那韦（Paxlovid）的剂量管理。
Clin Pharmacol Ther. 2022 Oct;112(4):803-807. doi: 10.1002/cpt.2687. Epub 2022 Jul 4.
4
An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir.艾司西酞普兰与细胞色素P450 3A4抑制剂利托那韦之间药代动力学相互作用可能性的评估。
Clin Ther. 2003 Apr;25(4):1200-10. doi: 10.1016/s0149-2918(03)80076-0.
5
Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone.基于生理的药代动力学建模以预测涉及抑制性代谢物的药物相互作用：胺碘酮的案例研究
Drug Metab Dispos. 2015 Feb;43(2):182-9. doi: 10.1124/dmd.114.059311. Epub 2014 Oct 16.
6
Evaluating the risk of drug-drug interactions with pharmacokinetic boosters: the case of ritonavir-enhanced nirmatrelvir to prevent severe COVID-19.评估与药代动力学增强剂发生药物相互作用的风险：以利托那韦增强型奈玛特韦预防重症 COVID-19 为例。
Clin Microbiol Infect. 2022 Aug;28(8):1044-1046. doi: 10.1016/j.cmi.2022.03.030. Epub 2022 Mar 28.
7
Verification of a physiologically based pharmacokinetic model of ritonavir to estimate drug-drug interaction potential of CYP3A4 substrates.验证基于生理的利托那韦药代动力学模型以评估CYP3A4底物的药物相互作用潜力。
Biopharm Drug Dispos. 2018 Mar;39(3):152-163. doi: 10.1002/bdd.2122.
8
Assessment of cytochrome P450-mediated drug-drug interaction potential of orteronel and exposure changes in patients with renal impairment using physiologically based pharmacokinetic modeling and simulation.使用基于生理的药代动力学建模和模拟评估奥特雄酮的细胞色素P450介导的药物相互作用潜力以及肾功能损害患者的暴露变化。
Biopharm Drug Dispos. 2014 Dec;35(9):543-52. doi: 10.1002/bdd.1919. Epub 2014 Oct 22.
9
Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir.与利托那韦增强型替拉那韦相关的药代动力学和药效学药物相互作用机制。
Pharmacotherapy. 2007 Jun;27(6):888-909. doi: 10.1592/phco.27.6.888.
10
Nirmatrelvir/ritonavir Use With Tacrolimus in Lung Transplant Recipients: A Single-center Case Series.尼马瑞韦/利托那韦联合他克莫司用于肺移植受者：一项单中心病例系列研究。
Transplantation. 2023 May 1;107(5):1200-1205. doi: 10.1097/TP.0000000000004394. Epub 2022 Oct 28.

引用本文的文献

1
Cardiovascular Drug Interactions with Nirmatrelvir/Ritonavir for COVID-19: Considerations for Daily Practice.用于治疗新冠肺炎的心血管药物与奈玛特韦/利托那韦的相互作用：日常实践中的考量
Eur Cardiol. 2024 Aug 9;19:e15. doi: 10.15420/ecr.2024.04. eCollection 2024.